Annual report pursuant to Section 13 and 15(d)

Intangible Assets - Narrative (Details)

v3.8.0.1
Intangible Assets - Narrative (Details)
1 Months Ended 4 Months Ended 12 Months Ended
May 02, 2016
USD ($)
agreement
$ / shares
shares
Jul. 31, 2016
USD ($)
$ / shares
shares
May 02, 2016
USD ($)
$ / shares
shares
Dec. 31, 2017
USD ($)
$ / shares
Dec. 31, 2016
USD ($)
$ / shares
Indefinite-lived Intangible Assets [Line Items]          
Indemnification period granted to former officers (in years) 6 years        
Shares of common stock issued | shares     234,297    
Shares issued, price per share (in dollars per share) | $ / shares       $ 1.35 $ 3.00
Licensing agreement term 3 years        
HPI option termination price $ 1,000,000   $ 1,000,000    
Houston Pharmaceuticals, Inc          
Indefinite-lived Intangible Assets [Line Items]          
Price per share of common stock issued (in dollars per share) | $ / shares   $ 6.00      
Accrued license agreement payment   $ 100,000      
Shares of common stock issued | shares   629,000      
HPI option termination price   $ 3,874,000   $ 3,874,000  
Moleculin LLC          
Indefinite-lived Intangible Assets [Line Items]          
Price per share of common stock issued (in dollars per share) | $ / shares $ 6.00   $ 6.00    
Loan to Moleculin $ 57,822   $ 57,822    
Royalty on net revenues (as a percent) 2.50%   2.50%    
Number of agreements with HPI | agreement 2        
Moleculin LLC | Acquisition Date One          
Indefinite-lived Intangible Assets [Line Items]          
Amortization of debt issuance costs and discounts excluded from pro forma         $ 145,078
Moleculin LLC | License Agreement | Houston Pharmaceuticals, Inc          
Indefinite-lived Intangible Assets [Line Items]          
Accrued license agreement payment $ 100,000   $ 100,000    
Shares of common stock issued | shares 629,000        
Shares issued, price per share (in dollars per share) | $ / shares $ 6   $ 6    
Payments to acquire intangible assets       300,000  
Moleculin LLC | Out-Lincense Agreement | Houston Pharmaceuticals, Inc          
Indefinite-lived Intangible Assets [Line Items]          
Licensing arrangements consideration payable $ 750,000   $ 750,000 750,000  
Licensing agreement term 3 years        
Payments to acquire intangible assets       1,000,000  
Licensing arrangements reserve       $ 1,000,000  
Common Stock | Moleculin LLC          
Indefinite-lived Intangible Assets [Line Items]          
Business acquisition, equity interest issued (in shares) | shares 999,931        
Business acquisition, value of equity interest issued $ 5,999,586   $ 5,999,586